Ann: Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting, page-66

Whilst I'm very excited about the prospect of updated results from the HER-Vaxx trial, to avoid disappointment I think everyone needs to cool their jets.

This announcement IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR from 2019 has the same disclaimer: "The content of the presentations are embargoed until the start of the conference and will be made available online after the start of the meeting and on the Imugene website."

Yes, it's great exposure to give a presentation at AACR, but no, I doubt it's setup to coincide with further/final results of the HER-Vaxx ph2 trial. (Although we may receive updated results in time for them to be talked about at AACR21.)

It's also worth bearing in mind the presentation is during the Phase I Clinical Trials session and it looks like it's a poster session and one of 47 presentations going on over a 3 hour period.